The Lysosomal-Mitochondrial Axis in Nonalcoholic Fatty Liver Disease

描述（由申请人提供）：非酒精性脂肪性肝病（NAFLD）是全球慢性肝病的主要原因，但其发病机制仍知之甚少。线粒体功能受损在很大程度上被认为是导致这种疾病进展的核心异常。现存的中心问题是什么事件将肝细胞中过量的脂质积累与线粒体功能障碍联系起来。因此，该提案的总体目标是确定导致NAFLD中线粒体功能障碍和疾病进展的细胞和分子机制。基于广泛的初步数据，我们提出了新的中心假设，即肝脏中过量的游离脂肪酸积累通过调节Bcl-2家族成员触发溶酶体透化而导致线粒体功能受损和NAFLD进展。我们现在将采用当前和互补的分子、生物化学和细胞生物学方法来进一步探索NAFLD中的溶酶体-线粒体轴。我们的建议有三个具体目标。首先，我们将在体外和体内NAFLD模型以及NAFLD和对照个体的人类样本中鉴定和操纵启动溶酶体透化的新型细胞内靶点。第二，我们将在分子水平上定义NAFLD模型和无细胞系统中的溶酶体-线粒体轴。最后，我们将确定在体外组织模型和体内饮食性NAFLD小鼠模型中，抑制溶酶体透化和组织蛋白酶B活化是否能预防肝损伤和纤维化。该提案在技术上和概念上都是创新的，因为它使用复杂的技术测试了脂质诱导肝毒性的新概念。此外，由于由于游离脂肪酸在非脂肪组织中过度积累导致的脂毒性已经涉及其他人类肝脏疾病的发病机制，包括慢性丙型肝炎感染、酒精性脂肪性肝炎和血色素沉着症，以及其他疾病如II型糖尿病和肥胖相关的心脏病，因此该提议的结果不仅可以为这些病症的机制带来新的见解，而且可以转化为治疗它们的新的治疗策略（例如，使用药理学Bax或组织蛋白酶B抑制剂）。

DESCRIPTION (provided by applicant): Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease worldwide, yet its pathogenesis remains poorly understood. Impaired mitochondrial function is largely thought to be a core abnormality responsible for disease progression in this condition. The central question extant is what events link excessive lipid accumulation in liver cells to mitochondrial dysfunction. Thus, the overall objective of this proposal is to define the cellular and molecular mechanisms contributing to mitochondrial dysfunction and disease progression in NAFLD. Based on extensive preliminary data, we propose the novel CENTRAL HYPOTHESIS that excessive free fatty acids accumulation in the liver results in impaired mitochondrial function and NAFLD progression by triggering lysosomal permeabilization via regulation of the Bcl-2 family members We will now employ current and complementary, molecular, biochemical and cell biological approaches to further explore the lysosomal - mitochondrial axis in NAFLD. Our proposal has three SPECIFIC AIMS. FIRST, we will identify and manipulate novel intracellular targets that initiate lysosomal permeabilization in in-vitro and in-vivo models of NAFLD as well as human specimens of NAFLD and control individuals. SECOND, we will molecularly define the lysosomal - mitochondrial axis in models of NAFLD and cell free systems. FINALLY, we will determine if inhibition of lysosomal permeabilization and cathepsin B activation prevent liver injury and fibrosis in an in-vitro tissue model and in-vivo dietary murine models of NAFLD. The proposal is innovative technically and conceptually as it tests new concepts for lipid induced hepatotoxicity using sophisticated technologies. Moreover, because lipotoxicity as a result of over-accumulation of free fatty acids in non-adipose tissues has been implicated in the pathogenesis of other human liver diseases including chronic hepatitis C infection, alcoholic steatohepatitis and hemochromatosis, as well as other diseases such as type II diabetes and obesity associated heart disease the results of this proposal may not only bring new insights to the mechanisms underlying these conditions, but also could translate into new therapeutic strategies to treat them (e.g. the use of pharmacological Bax or cathepsin B inhibitors).